tiprankstipranks
Trending News
More News >

Kymera Therapeutics upgraded to Overweight from Equal Weight at Morgan Stanley

Morgan Stanley upgraded Kymera Therapeutics (KYMR) to Overweight from Equal Weight with a price target of $79, up from $49. The company reported Phase 1 data for STAT6 degraded KT-621 thtat the firm believes addressed key questions on safety and target knockdown, the analyst tells investors in a research note. The firm added that the data increases its confidence in KT-621’s ability to compete across large immunology and inflammation indications and in Kymera’s platform more broadly.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue